Key highlights
- US September-quarter Revenue at Cyclopharm (ASX:CYC) reached AUD 1.62 million, up 124% year on year.
- Cyclopharm counted 84 installed US Technegas systems at 30 September.
- Group revenue for the first nine months reached AUD 25.9 million.
A morning rise of 6.82% took Cyclopharm (ASX:CYC) to AUD 0.470 at 11:52 a.m. AEDT on 20 November 2026. The S&P/ASX 200 was lower during the session. The nuclear medicine company reported quarterly US Technegas sales and installation figures on 29 October 2026.
US Technegas revenue increased in the September quarter
Cyclopharm’s 29 October 2026 update reported unaudited US revenue of AUD 1.62 million for the September quarter, up 124% from the corresponding 2025 quarter and 45% from the preceding quarter. US revenue for the first nine months was AUD 3.8 million. The company attributed 76% of quarterly US sales to consumable orders from existing sites, compared with 58% in the June quarter. Its commercial model combines installing a Technegas system with ongoing sales of consumables used in scans. The quarterly revenue mix reflects those activities at sites already operating and at newer installations.
Installation figures and procurement stages
The company counted 84 systems installed in the United States at 30 September, compared with 46 at 31 March. It also reported changes in separate procurement categories during the period between 12 August and quarter end. Primary sites at committee review rose from 109 to 186, and those in contract review increased from 44 to 71. The number of locations described as on hold fell from 220 to 190. Each category represents a different stage of hospital procurement, and an installed system sits further along the process than one still under committee or contract review. Quarterly reporting included 14 system installations, of which 13 took place in September. The company’s revenue table recorded AUD 1.30 million of patient consumables and AUD 0.32 million of installation revenue. Cyclopharm had 110 systems in US inventory ready for deployment at quarter end.
Group revenue and use of cash
Cyclopharm’s unaudited group revenue for the nine months to 30 September was AUD 25.9 million, up 13.7% year on year. It held AUD 9.6 million in cash at quarter end. Average monthly net cash burn in Q3 was AUD 0.9 million, which the company calculated using the average monthly reduction in cash before financing for the period. US sales represent part of the group’s revenue, and the installation and consumables figures describe activity in the company’s US rollout. The company did not provide Earnings or installation guidance in the October presentation.
Lung imaging and hospital adoption
Technegas is used for lung ventilation imaging. Its use in ventilation and perfusion scanning sits within hospital diagnostic services, with purchases going through hospital review and contracting. Cyclopharm received US FDA approval for Technegas in late 2023 as a drug-device combination. Since then, the company has tracked how sites move from commercial engagement through procurement to installation and use. The quarter’s increase in consumable revenue covers orders at sites already holding a system. Installation figures and recurring usage are two distinct measures of how the company’s US activity is developing over time.
Procurement and ongoing usage can vary
Hospital committee and contract reviews can take different lengths of time across health systems. The company’s commercial pipeline counts primary sites at stages before installation and may also reference affiliated locations covered by a hospital network. The timing of equipment Placement and the level of subsequent use affect the mix of installation and consumable revenue. The October update includes unaudited management figures and notes that cash receipts can vary by month. A quarterly average therefore describes the cash movement over that period and can differ from individual monthly balances.
The US rollout in upcoming reporting
Further updates can track how many sites move from review to signed contracts and installation, and how much revenue comes from consumables at existing locations. A period-on-period comparison also allows the pace of US activity to be read alongside group revenue and cash use. Cyclopharm has been reporting the hospital pipeline by stages, giving a way to follow developments before sites begin using the system. The September baseline gives those later updates a reference point for installed systems and use of consumables. The company’s reporting distinguishes actual installations from hospital procurement activity.
The September position
Cyclopharm recorded higher US revenue and installations, and existing customer sites accounted for most quarterly US sales through consumable orders.

_11_20_2026_05_22_52_194526.jpg)




Please wait processing your request...